THERAPEUTIC MODALITIES Archives - Page 4 of 24

End-to-End CRDMO Platform for Oligonucleotide Drugs

Since the approval of the first siRNA drug in 2018, oligonucleotide therapeutics have rapidly emerged as a promising drug modality. ...

Integrated Platform Supporting ASO Drug Discovery

Antisense oligonucleotides (ASOs) are single-stranded, synthetic chains of DNA or RNA designed to bind to specific RNA sequences through complementary...

Evaluating Off-Targets of siRNA Drugs

siRNA holds great promise as a therapeutic modality due to its high specificity, developability, and sustained efficacy. However, its application...

Efficacy of a Cell Therapy Drug on Kainic Acid-Induced Seizures

Epilepsy is one of the most common neurological disorders, and cell therapy is a promising area of research that has...

PBMC Humanized Tumor Models for Evaluating T-cell Engagers

T-cell engagers (TCEs) are a class of bispecific antibody-based immunotherapies designed to bring T cells into close proximity with cancer...

Innovative Technologies in Early Drug Discovery

In this webinar, WuXi AppTec scientists discuss the latest innovative technologies and products in early-stage drug discovery. Viewers will gain...

Application of On-bead DEL Technology in Target Protein Degradation Phenotypic Screen

DNA-encoded library (DEL) technology has been recognized as a major screening method, offering unique advantages through its ability to provide...

Strategies for Advancing Molecular Glue Drug Discovery

In this webinar, WuXi Biology scientists showcase our end-to-end molecular glue discovery platform. Molecular glues act as “molecular adhesives”, facilitating...